Spero Therapeutics (SPRO) Restructuring Costs (2022 - 2025)

Spero Therapeutics' (SPRO) quarterly Restructuring Costs came in at $83000.0 in Q2 2025, down 52.57% on a QoQ basis from $175000.0 in Q1 2025.

Spero Therapeutics (SPRO) Restructuring Costs (2022 - 2025) Analysis & Trends

Spero Therapeutics (SPRO) has 3 years of Restructuring Costs data on file, last reported at $83000.0 in Q2 2025.

Quarterly Restructuring Costs changed N/A year-over-year to $83000.0 in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $83000.0 (down 92.11% YoY) and the FY2025 annual result came in at $258000.0, down 70.58% from the prior year.
Restructuring Costs declined to $83000.0 in Q2 2025, from $175000.0 in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $877000.0 in Q4 2024 to a low of -$152000.0 in Q3 2022.
A 3-year average of $183200.0 and a median of $83000.0 in 2025 frame the typical range for Restructuring Costs.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Spero Therapeutics	70.14 Mn	19.37 Mn	-

Download Data